Aardvark Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $81.70M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 12, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 11, 2026 | After market close | – | $-0.66 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | Before market open | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 23, 2026 | After market close | – | $-0.81 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 13, 2025 | After market close | – | $-0.75 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 13, 2025 | After market close | – | $-0.66 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 14, 2025 | After market close | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 31, 2025 | After market close | – | – | – |
Press releases
Announcements Aardvark Therapeutics filed with the SEC
Aardvark Therapeutics Appoints Clinical Development Leader David Zhang, Ph.D., MBA, to its Board of Directors
Executive or director change · Other events · EX-99.1 to Form 8-K
Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Aardvark Therapeutics Plans to Unblind HERO and OLE Data to Inform Path Forward Following FDA Clinical Hold
Other events · EX-99.1 to Form 8-K
Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Aardvark Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Aardvark Therapeutics Announces Voluntary Pause of Phase 3 HERO Trial in
Other events · EX-99.1 to Form 8-K
Aardvark Therapeutics Announces Establishment of New U.S. Subsidiary to Support Development of Its Dermatology Pipeline; Bryan Jones Named Chief Executive Officer
Executive or director change · Other events · EX-99.1 to Form 8-K
Aardvark Therapeutics Announces Leadership Appointments
Executive or director change · Other events · EX-99.2 to Form 8-K
Corporate Presentation January 2026 Exhibit 99.1
Other events · EX-99.1 to Form 8-K
Aardvark Therapeutics Announces First Patient Dosed in Australia in HERO Phase 3 Trial for Prader-Willi Syndrome
Other events · EX-99.1 to Form 8-K
Aardvark Therapeutics Reports Third Quarter 2025 Financial Results and Provides Pipeline and Business Updates
Results of operations · EX-99.1 to Form 8-K
ObesityWeek Investor Webinar November 5, 2025 Exhibit 99.1
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Aardvark Therapeutics Presents Data Supporting its Metabolic Obesity Pipeline Programs at ObesityWeek 2025
Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
Aardvark Therapeutics Announces FDA Alignment on Protocol Amendment Expanding Phase 3 HERO Trial Population for Prader-Willi Syndrome
Other events · EX-99.1 to Form 8-K
Hunger vs Appetite: Distinct Neural Pathways Appetite Hunger Penalty avoidance Mediated by local gut hormones like CCK Signaling through the Gut-Brain Axis Reward-based Mediated by circulating hormones like GLP-1 Targeted systemically through the bloodstream CCK, cholecystokinin; GLP-1, glucagon-…
Other events · EX-99.1 to Form 8-K
Aardvark Therapeutics Reports Second Quarter 2025 Financial Results and Provides Pipeline and Business Updates
Results of operations · EX-99.1 to Form 8-K
Aardvark Therapeutics Reports First Quarter 2025 Financial Results and
Results of operations · EX-99.1 to Form 8-K
Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights
Results of operations · EX-99.1 to Form 8-K